Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Thrilled to share new real-world data from Germany comparing three extended half-life Factor IX products for Haemophilia B prophylaxis: rIX-FP, rFIXFc, and N9-GP!
Multicenter chart review of 138 patients (mean age ~33 years) with moderate or severe haemophilia B from 31 centers and analysis of FIX consumption, dosing intervals, and bleeding rates over ~2 years:
Results
– Over 1/3 of rIX-FP and rFIXFc users achieved zero bleeds in the observation period, highlighting effective bleed prevention
– rIX-FP showed significantly lower FIX consumption (46.9 IU/kg/week) than rFIXFc (70.1 IU/kg/week) and similar to N9-GP (47.2 IU/kg/week)
– Extension of dosing intervals: Mean interval with rIX-FP reached 9.4 days, allowing less frequent infusions compared to 7.5 (rFIXFc) and 7.9 days (N9-GP)
Bleed rates: rIX-FP patients had lower annualised bleeding rates (ABR 0.8) vs. N9-GP (ABR 1.5, p=0.047) and comparable to rFIXFc (ABR 1.4)
Clinical Impact:
- EHL FIX products offer flexible prophylaxis tailored to patient needs—key for supporting active lifestyles and improving adherence!
- Real-world evidence builds confidence for clinicians considering switching or individualizing FIX therapy
Congratulations to the authors, PD Dr. Martin Olivieri and co-authors and thank you to CSL for supporting this study and generating robust evidence that advances patient-centered care in haemophilia B.”
Read the full article here.
Article: Comparing Real‑World Outcomes of Prophylaxis with Extended Half‑life Factor IX (rIX‑FP vs. rFIXFc and N9‑GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany
Authors: Martin Olivieri, Songkai Yan, Ying Yang , Radovan Tomic, Thomas Linhoff, Xiang Zhang, Douglass Drelich,Natalie Jakobs, Wolfgang Miesbach
Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61
-
Apr 22, 2026, 07:34Aikati Anastasiou: Advancing Stroke Imaging Insights from the DISTAL Trial
-
Apr 22, 2026, 07:26Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
-
Apr 22, 2026, 07:19Sarah Richardson: Bringing Insights from HFA Symposium Back to Real Life
-
Apr 22, 2026, 07:17Karuna Kumar: Interesting Trial from Gambia on Treating Iron Deficiency in Children
-
Apr 22, 2026, 07:12Mary Catherine Moffett: Celebrating 32 Years of Patient-Centered Advocacy with the Hemophilia Federation of America